Abstract :
To evaluate the pharmacokinetics of compound K after oral administration of HYFRG and RG in humans, an open-label, randomized, single-dose, fasting, and one-period pharmacokinetic study was conducted. After oral administration of a single 3 g dose of HYFRG and RG to 24 healthy Korean males, the mean ([+ or -]SD) of [AUC.sub.0-t] and [C.sub.max] of compound K from HYFRG were 1466.83 [+ or -] 295.89 ng-h/mL and 254.45 [+ or -] 51.20 ng/mL, being 115.2 -and 80-fold higher than tlx ose for RG (12.73 [+ or -] 7.83 ng-h/mL and 3.18 [+ or -] 1.70 ng/mL), respectively; in case of Sprague Dawley rats the mean ([+ or -]SD) of [AUC.sub.0-t] and [C.sub.max] of compound K from HYFRG was 58.03 [+ or -] 32.53 ng-h/mL and 15.19 [+ or -] 10.69 ng/mL, being 6.3- and 6.0-fold higher than those from RG (9.21 [+ or -] 7.52 ng-h/mL and 2.55 [+ or -] 0.99 ng/mL), respectively. [T.sub.max] of compound K in humans and rats was 2.54 [+ or -] 0.92 and 3.33 [+ or -] 0.50 h for HYFRG and 9.11 [+ or -] 1.45 and 6.75 [+ or -] 3.97 hours for RG, respectively. In conclusion, the administration of HYFRG resulted in a higher and faster absorption of compound K in both humans and rats compared to RG.